Jafron Biomedical overhauls governance, expands business scope

Jafron Biomedical's board of directors approved substantial revisions to its organizational structure and Articles of Association, subject to shareholder approval at an extraordinary general meeting on December 11, 2025. Key changes include replacing the Board of Supervisors with a Board Audit Committee and renaming the "General Meeting of Shareholders" to "Shareholders' Meeting." The "Board Strategy Committee" will also be renamed the "Board Strategy and ESG Committee," reflecting an increased focus on environmental, social, and governance responsibilities.

The company's business scope will expand to include "sales of electronic components and electromechanical assembly equipment; sales of mechanical parts and components; sales of metal products; sales of metal materials," aiming to support its growth strategy. Additionally, new and revised governance policies, such as a "Remuneration Management System for Directors and Senior Management" and an "FX Hedging Business Management System," were introduced to enhance operational efficiency and risk management.

Shareholders will vote on these proposals at the upcoming meeting, with certain critical resolutions requiring a two-thirds majority. These changes aim to modernize Jafron Biomedical's governance in line with updated regulations and its strategic development plans.